Tag: scheme-between

Britain's healthcare cost watchdog has finally approved GlaxoSmithKline's lupus drug Benlysta for limited use, after rejecting it since 2011 on the grounds that it failed to offer good value for money. The National Institute for Health and Care Excellence (NICE) said on Tuesday that the drug would be made available under a managed access scheme…